Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
AstraZeneca has agreed to pay $4 billion for a 55% stake in privately held Acerta Pharma. The centerpiece of the deal is acalabrutinib, a second-generation BTK inhibitor in Phase III studies to treat certain blood cancers. If successful, the molecule would compete with Imbruvica, an approved BTK inhibitor developed by Pharmacyclics, which AbbVie acquired earlier this year for $21 billion. AstraZeneca has also secured an option to acquire the remaining shares in Acerta for roughly $3 billion.
This article has been sent to the following recipient: